Switzerland-headquartered Nasdaq- and Iceland-listed Oculis Holding, a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases, has priced an underwritten offering of 5,000,000 of its ordinary shares at…
Switzerland: Oculis raises US$100m from underwritten share issue
…
…






